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Carcinoma ex Pleomorphic Adenoma of the Salivary Glands: 
Distinct Clinicopathologic Features and Immunoprofiles 
Between Subgroups According to Cellular Differentiation
In carcinoma ex pleomorphic adenoma (CXPA), pleomorphic adenoma (PA) and diverse 
carcinoma components showing luminal (ductal) or non-luminal (myoepithelial) 
differentiation coexist. To elucidate the clinicopathological implications of cellular 
differentiation in CXPA and the potential role of p53, vascular endothelial growth factor 
(VEGF), c-erbB-2, c-kit, and glucose transporter 1 (Glut-1) in carcinogenesis, we analyzed 
11 CXPAs with luminal differentiation (CXPAs-LD) and 6 CXPAs with non-luminal 
differentiation (CXPAs-NLD) and compared protein expressions in residual PAs and 
carcinomas by immunohistochemistry. Among the CXPAs-LD, 5 were invasive and 8 were 
histologically high-grade tumors. The 5-year survival rate was 72.7%. P53, c-erbB-2, 
VEGF, and Glut-1 were more immunoreactive in carcinoma components than in PAs 
(P = 0.008, 0.004, 0.002, and 0.024, respectively); c-erbB-2 overexpression was 
associated with high histological grade (P = 0.024). Carcinoma components frequently 
lacked c-kit expression (P = 0.009). CXPAs-NLD were all low-grade and invasive with a 
larger mean tumor size (5.2 cm) than CXPAs-LD (3.3 cm) (P = 0.040). The patients 
remained disease-free without significant immunohistochemical expression. The 
immunoprofiles and clinical course of CXPA differed according to cellular differentiation. 
Therefore, it is important to report the histological subtype and to assess potential 
biomarkers in diagnostic and therapeutic trials. 
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INTRODUCTION
Carcinoma ex pleomorphic adenoma (CXPA) is a rare and poor-
ly understood malignancy that develops from either a long-stand-
ing primary or a recurrent pleomorphic adenoma (PA). Among 
salivary gland tumors, CXPA is unique and interesting because 
it is histologically diverse and contains both benign pleomor-
phic adenoma and carcinomatous components. Most types of 
salivary epithelial carcinomas have been reported as malignant 
components of CXPA, and the morphological variability of CX-
PAs makes it difficult to investigate and elucidate the mechanisms 
of the underlying malignant transformation in PAs (1-3).
  The carcinogenesis of CXPA is still unclear; however, it is prob-
ably because of the accumulation of genetic instabilities. CXPAs 
can be classified into 2 main subtypes according to their mor-
phological and immunohistochemical features. The first sub-
type comprises carcinomas with luminal (ductal epithelial) dif-
ferentiation (CXPA-LD) such as adenocarcinoma, not otherwise 
specified (NOS); salivary duct carcinoma (SDC); and mucoepi-
dermoid carcinoma (MEC). The second subtype comprises car-
cinomas with non-luminal (myoepithelial) differentiation (CX-
PA-NLD) such as myoepithelial carcinoma (MC), epithelial-myo-
epithelial carcinoma (EMC), and adenoid cystic carcinoma (4). 
Since the concept of carcinoma in situ (intraductal carcinoma) 
has been recently proposed to be an early phase of malignant 
transformation in CXPA-LD, some studies have investigated an-
cillary biomarkers for carcinoma in situ (5-7). In CXPA-LD, the 
malignant transformation of ductal epithelial cells may follow a 
stepwise sequence and manifest as 1) carcinoma in situ, in which 
carcinoma cells replace the normal inner ductal epithelial layer 
while retaining the peripherally located intact myoepithelial lay-
er; 2) intracapsular carcinoma, in which carcinoma cells break 
through the myoepithelial layer and invade the matrix of a pre-
existing PA without capsular invasion; or 3) extracapsular inva-
sive carcinoma, in which the invasion extends to the extracap-
sular area. In the recent World Health Organization (WHO) clas-Kim JW, et al.  •  Immunoprofiles of Carcinoma ex Pleomorphic Adenoma
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sification, carcinoma in situ or intraductal carcinoma and intra-
capsular carcinoma are included in “noninvasive” CXPA, and 
extracapsular carcinoma is defined as “invasive” CXPA (8). 
  However, this concept of carcinoma in situ cannot be appli-
cable to CXPA-NLD. Further, there is only limited information 
on the differences in their pathogenesis and clinical outcome, 
although CXPAs-NLD exhibit histological features quite differ-
ent from those of CXPAs-LD (9-11). Hence, the study of CXPAs 
according to cellular differentiation may give insights into the 
pathogenesis of CXPA and help in determining a treatment ap-
proach in the absence of definitive clinical trials, which are dif-
ficult to conduct because of the rarity of CXPA cases.
  In this study, we compared the clinicopathological character-
istics of the CXPA-LD and CXPA-NLD groups. Moreover, to in-
vestigate the potential values of biomarkers associated with the 
development and progression of carcinoma in each group, we 
examined the expression of the immunohistochemical markers 
p53, endothelial growth factor receptor (EGFR), vascular endo-
thelial growth factor (VEGF), c-erbB-2, c-kit, Bcl-2, and glucose 
transporter 1 (Glut-1) in carcinomas and residual PAs. To the 
best of our knowledge, a comparative study for these immuno-
profiles between CXPA groups according to cellular differentia-
tion has not been reported earlier.
MATERIALS AND METHODS
Patient selection and histopathological analysis
The cases of 17 CXPA patients were studied. Their records were 
retrieved from the surgical pathology database of the Asan Med-
ical Center between 1996 and 2006. All patients underwent an 
operation. Demographic, clinical, and follow-up data were col-
lected from the patients’ medical records in such a manner that 
subjects cannot be identified. Using ancillary immunohisto-
chemical stains for p63 and smooth muscle actin (SMA), by a 
previously described method, we classified the CXPAs into 2 
groups according to the cellular differentiation of the carcino-
ma component: with LD and with NLD (4). Further, the histo-
logical subtype of the malignant component was defined accord-
ing to WHO classification of salivary gland tumors (12). Hema-
toxylin-eosin-stained slides of tumor samples from all the study 
patients were reviewed by 2 pathologists to confirm the diagno-
sis. Other histological findings, including invasiveness accord-
ing to the WHO criteria (noninvasive, minimally invasive, and 
frankly invasive), histological subtype, tumor necrosis, presence 
of prominent stromal hyalinization, lymphovascular tumor in-
vasion (LVI), perineural invasion (PNI), status of microscopic 
resection margin, and estimated proportion of residual PA, were 
also examined. The tumors were histologically examined and 
classified as high grade (when  ≥ 2 of the following features were 
observed: anaplasia with nuclear pleomorphism and prominent 
nucleolus, frequent mitoses [ ≥ 5 per 10 high-power fields], atyp-
ical mitosis, and extensive coagulative tumor necrosis) or low 
grade. 
Immunohistochemistry 
The tissue blocks containing both the malignant area and benign 
PA were selected. We mounted 4-µm thick sections on precoat-
ed glass slides; these were deparaffinized in xylene and dehy-
drated in descending grades of ethanol. Immunohistochemical 
assays were performed using the Ventana NX automated im-
munohistochemistry system (Ventana Medical Systems, Tuc-
son, AZ, USA) with monoclonal/polyclonal primary antibodies 
to SMA (dilution, 1:200; Clone 1A4; Neomarkers, Fremont, CA, 
USA), p63 (dilution, 1:50; Clone 7JUL; Novocastra, Newcastle, 
UK), p53 (dilution, 1:3000; Code M7001; Dako, Glostrup, Den-
mark), EGFR (dilution, 1:50; Clone EGFR.113; Novocastra), VEGF 
(dilution, 1:400; Clone G153-694; Pharmingen, San Diego, CA, 
USA), c-erbB-2 (dilution, 1:500; Code A0485; Dako), c-kit (dilu-
tion, 1:200; Code A4502; Dako), Bcl-2 (dilution, 1:25; Clone 124; 
Dako), and Glut-1 (dilution, 1:100; Clone SPM498; Neomarkers). 
Interpretation of immunohistochemical staining patterns
Evaluation of immunohistochemical staining patterns in each 
malignant component and residual PA and reassessment of dis-
cordant results were performed by 2 pathologists. p53 staining 
was scored by combining both the percentage of positive tumor 
cells and the staining intensity (5). A factor for the intensity of 
staining (0, none; 1, weak; 2, moderate; and 3, strong) and a fac-
tor for the total percentage of positively stained cells (1, 1%-20%; 
2, 21%-50%; 3, 51%-80%; and 4, 81%-100%) were multiplied, with 
the cutoff value for a positive reaction being a score of 4; this has 
previously yielded useful results (13). The immunostaining re-
sults of EGFR and c-erbB-2 were scored as follows: 0, no reactiv-
ity or membranous staining in  ≥ 10% of the tumor cells; 1+, faint/ 
barely perceptible membranous staining in ≥ 10% of tumor cells; 
2+, weak to moderate complete membrane staining in ≥ 10% of 
tumor cells; and 3+, strong complete membrane staining in ≥ 10% 
of tumor cells. Scores of 2+ and 3+ were considered a positive 
reaction (14, 15). C-kit expression was defined by membranous 
reactivity in ≥ 10% of the cells (16). VEGF staining was scored by 
combining both the percentage of positive tumor cells and the 
staining intensity, defined as low (< 20% of tumor cells showing 
weak positivity) or high (≥ 20% of tumor cells showing moder-
ate or strong positivity); high staining indicated overexpression 
of VEGF (17). Glut-1 expression was considered positive only if 
distinct membrane staining was observed. All patients were di-
vided into the following 2 groups according to their Glut-1 ex-
pression level: low-expression group (< 15%) and high-expres-
sion group (≥ 15%) (18). Positive expression of p63 and Bcl-2 
was identified by unequivocal nuclear staining, and that of SMA, 
by cytoplasmic staining of neoplastic cells.
 Kim JW, et al.  •  Immunoprofiles of Carcinoma ex Pleomorphic Adenoma
http://jkms.org   1279 http://dx.doi.org/10.3346/jkms.2011.26.10.1277
Statistical analysis
The clinicopathological variables and the incidence of overex-
pression detected by immunohistochemical staining were com-
pared by t test and Pearson’s chi-square test. The Cox propor-
tional hazard model was used for multivariate analysis, and the 
5-yr survival rate was calculated by the Kaplan-Meier method. 
All statistical analyses were performed using the Statistical Pack-
age for Social Sciences software program, version 17.0 (SPSS Inc., 
Chicago, IL, USA), and the results were considered statistically 
significant when the P value was  ≤ 0.05.
Ethics statement
Institutional review board exempted review of this study protocol 
on the basis of being a study of existing pathological specimens.
RESULTS
Histological findings and clinical course
CXPA-LD was predominant and was observed in 11 (64.7%) pa-
tients (Table 1). It was found to be more prevalent in men than 
in women (8 men and 3 women). The mean age of the patients 
was 50.6 yr, and the mean size of the tumors was 3.3 cm. The his-
tological subtype of the malignant component was classified as 
adenocarcinoma, NOS in 5 tumors, MEC in 4, and SDC in 2 tu-
mors (Table 2). There were 8 tumors of a histologically high grade 
and 3 tumors of low grade. All high-grade tumors, except for 1, 
had a prominent hyalinized stroma and coagulative tumor ne-
crosis. Low-grade tumors however did not show stromal hyalin-
ization or necrosis. The percentage of the malignant component 
ranged from 45% to 95% (mean, 75.5%). There were 5 invasive, 3 
minimally invasive, and 3 noninvasive carcinomas. Of the 5 pa-
tients with invasive CXPAs-LD, 3 (27.3%, 2 of high grade and 1 
of low grade) died from the disease. One with high-grade adeno-
carcinoma, NOS, a positive surgical margin, and regional lymph 
node metastasis died 2 months after the operation and radiation 
therapy. Another patient with high-grade SDC and lymph node 
metastasis showed disease recurrence and underwent radio-
therapy but died 15 months after the operation, and 1 patient 
with low-grade adenocarcinoma, NOS developing from recur-
rent PA was treated with chemotherapy for distant metastasis to 
the lung but died 21 months after the operation. The 5-yr sur-
vival rate was 72.7%, and the disease mortality rate was higher 
in CXPA-LD than in CXPA-NLD; however, the difference was 
not statistically significant (P = 0.178). 
  CXPA-NLD, which showed positive reactions for p63 and SMA 
and demonstrated myoepithelial differentiation, was observed 
in 6 (35.3%) patients, with equal numbers of men and women 
being affected. The mean age of the patients was 56.2 yr and the 
mean size of the tumors was 5.2 cm, which was larger than that 
of CXPA-LD (P = 0.040). The tumors developed from a primary 
PA. The histological subtype of the malignant component was 
Table 1. Clinical parameters of study population and 5-yr survival rate
Parameters
CXPA
LD (n = 11) NLD (n = 6)
Age (yr, mean ± SD) 50.6 ± 12.0 56.2 ± 9.9
Male:Female 8:3 3:3
Size (cm, mean ± SD) 3.3 ± 1.6 5.2 ± 1.9
Site 
   Parotid gland
   Submandibular gland
   Minor salivary gland*
 
  9 
  0
  2
 
5
1
0
Primary PA vs recurrent PA
   Primary
   Recurrent
 
10
  1
 
6
0
Treatment
   Surgery alone
   Surgery and RT
   Surgery and CT
   Surgery and RT and CT
 
  4
  5
  1
  1
 
3
3
0
0
Follow-up period (mo, mean ± SD) 54.9 ± 37.6 73.0 ± 34.0
5-yr survival rate (%) 72.7 100
*Located in parapharynx (n = 2). CXPA, carcinoma ex pleomorphic adenoma; PA, 
pleomorphic adenoma; LD, luminal differentiation; NLD, non-luminal differentiation; n, 
number of cases; yr, years; SD, standard deviation; RT, radiation treatment; CT, che-
motherapy; mo, months.
Table 2. Histopathologic features and clinical outcome of carcinoma ex pleomorphic adenoma with luminal differentiation
Case
Histologic  
subtype
Histologic  
 grade
Invasi- 
veness
Tumor  
necrosis
Stromal  
hyalinization
LVI or PNI
LN  
metastasis
Local  
recurrence
Distant  
metastasis
DOD
  1 Adenoca High NI No No No No No No No
  2 Adenoca High INV Presence Presence Presence Presence Presence No Yes
  3 Adenoca High INV Presence Presence Presence No No No No
  4 Adenoca Low NI No No No No No No No
  5 Adenoca Low INV No No No No No Presence Yes
  6 MEC High MI Presence Presence No No No No No
  7 MEC High MI Presence Presence No No No No No
  8 MEC High INV Presence Presence No No No No No
  9 MEC Low MI No No No No No No No
10 SDC High NI Presence Presence No No No No No
11 SDC High INV Presence Presence Presence Presence Presence No Yes
Adenoca, adenocarcinoma, not otherwise specified; MEC, mucoepidermoid carcinoma; SDC, salivary duct carcinoma; NI, noninvasive; INV, invasive; MI, minimally invasive; LVI, 
lymphovascular tumor invasion; PNI, perineural invasion; LN, lymph node, DOD, died of disease.Kim JW, et al.  •  Immunoprofiles of Carcinoma ex Pleomorphic Adenoma
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MC in 3 tumors and EMC in 3 tumors (Table 3). All tumors were 
low-grade and invasive. All the 3 MCs and 1 EMC showed hya-
linized stroma. One MC displayed coagulative necrosis. The per-
centage of the malignant component ranged from 38% to 90% 
(mean, 85.0%). No tumor showed lymph node metastasis. All 
patients remained disease-free after surgical excision irrespec-
tive of whether they received postoperative radiation treatment. 
Immunohistochemical analysis
In CXPA-LD, p53, VEGF and Glut-1 was more often overexpress-
ed in the carcinoma components than in the residual PA com-
ponents (P = 0.008, 0.002, and 0.024, respectively) (Table 4). Posi-
tive staining for c-erbB-2 (score, 3+) was observed in the carci-
noma components of 7 tumors but not in the PA components 
(P = 0.004) (Fig. 1). Moreover, c-erbB-2 overexpression was as-
sociated with a high histological grade (P = 0.024). Typical ex-
amples of different patterns of immunoreactivity for c-kit are 
shown in Fig. 2. We observed that c-kit was expressed in the lu-
minal cells of the PA but not in the myoepithelial cells. Immu-
nopositivity of c-kit was found in the PA component of 9 tumors 
Table 3. Histopathologic features and clinical outcome of carcinoma ex pleomorphic adenoma with non-luminal differentiation
Case
Histologic  
sutype
Histologic  
grade
Invasi- 
veness
Tumor  
necrosis
Stromal  
hyalinization
LVI or PNI
LN  
metastasis
Local  
recurrence
Distant  
metastasis
DOD
12 MC Low INV No Presence No No No No No
13 MC Low INV No No No No No No No
14 MC Low INV No No No No No No No
15 EMC Low INV Presence Presence No No No No No
16 EMC Low INV No Presence No No No No No
17 EMC Low INV No Presence No No No No No
MC, myoepithelial carcinoma; EMC, epithelial-myoepithelial carcinoma; NI, noninvasive; INV, invasive; MI, minimally invasive; LVI, lymphovascular tumor invasion; PNI, perineural 
invasion; LN, lymph node, DOD, died of disease.
A B
C D
Fig. 1. In CXPA-LD, strong immunohistochemical staining for p53 (A), c-erbB-2 (B), VEGF (C), and Glut-1 (D) was observed in the malignant components (top right), whereas no 
immunohistochemical reaction to the biomarkers was observed in the residual PA components (bottom left).Kim JW, et al.  •  Immunoprofiles of Carcinoma ex Pleomorphic Adenoma
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(81.8%), whereas the carcinoma components of 9 tumors lacked 
c-kit expression (P = 0.009). Overexpression of EGFR (score, 2+) 
was noted in the malignant components of 3 tumors (27.3%) and 
in the residual PA of 1 tumor (9.1%). Bcl-2 was weakly stained in 
the carcinoma component of only 1 sample. No biomarker was 
found to be associated with invasiveness, and no significant 
prognostic factor was identified in the Cox proportional hazard 
model. 
  In CXPA-NLD, Bcl-2 and Glut-1 were more frequently express-
ed in the malignant component than in the benign component; 
however, the difference was statistically non-significant. Two 
carcinoma components were faintly stained for c-erbB-2 (score, 
1+) (Fig. 3). Immunohistochemical staining for p53, VEGF, and 
EGFR showed no significant difference in expression between 
the benign and malignant components. C-kit immunostain was 
expressed in the residual PA of 5 tumors (83%). In the carcino-
A B
C D
Fig. 2. C-kit expression in residual PA and malignant components. In PA, strong membranous positivity was noted in the luminal cells of duct-like structures (A, B-top right), but 
in noninvasive and invasive components of CXPA-LD, the result of c-kit immunohistochemical staining was negative (B-bottom left and C). In CXPA-NLD with EMC subtype, c-
kit was expressed only in the inner luminal cells of ductal structures (D).
Table 4. Immunohistochemical expression status of carcinoma and residual pleomorphic adenoma in carcinoma ex pleomorphic adenomas
Antibody
CXPA-LD (n = 11)  CXPA-NLD (n = 6)
Residual PA (%) Carcinoma (%) P value Residual PA (%) Carcinoma (%) P value
p53    1 (9.1)   8 (72.7) 0.008 0 (0)      1 (16.7) NS
c-erbB-2 0 (0)   7 (63.6) 0.004 0 (0) 0 (0) NS
VEGF      2 (18.2) 10 (90.9) 0.002   3 (50)   3 (50) NS
Glut-1    1 (9.1)   7 (72.7) 0.024      2 (33.3)      5 (83.3) 0.242
EGFR    1 (9.1)   3 (27.3) 0.586 0 (0)      1 (16.7) NS
Bcl-2 0 (0) 1 (9.1) NS 0 (0)   3 (50) 0.182
C-kit      9 (81.8)   2 (18.2) 0.009   5 (83)      2 (33.3) 0.242
n, number of cases with overexpression; CXPA-LD, carcinoma ex pleomorphic adenoma with luminal differentiation; CXPA-NLD, carcinoma ex pleomorphic adenoma with non-
luminal differentiation; NS, not significant.Kim JW, et al.  •  Immunoprofiles of Carcinoma ex Pleomorphic Adenoma
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ma components, c-kit was not expressed in the MC subtype but 
was focally expressed only in the inner duct-like structure of 2 
EMCs (33.3%, P = 0.242) (Fig. 2).
  In addition, we compared the expression rate of biomarkers 
in malignant components between CXPA-LD and CXPA-NLD 
and found that p53 and c-erbB-2 overexpression was significant-
ly frequent in the malignant component of CXPA-LD (P = 0.050 
and 0.035, respectively) (Fig. 4).
DISCUSSION
Carcinoma ex pleomorphic adenoma (CXPA) is the third com-
mon malignancy of the salivary gland and comprises approxi-
mately 3.6% of all salivary tumors and 12% of all salivary malig-
nancies (19). Recently, Altemani et al. reported the following 2 
types of carcinomas arising in a PA: 1) CXPAs composed of ma-
lignant epithelial cells, which have an immunoprofile compa-
rable to that of ductal luminal cells in a PA and are probably de-
rived from cells already committed to differentiation into ductal 
luminal cells and 2) CXPAs composed of myoepithelial cells, 
which are likely derived from a common precursor of myoepi-
thelial and ductal cells (bipotent cell) (4, 20).
  Here, we compared the CXPA-LD and NLD groups with re-
spect to biomarker expression and clinical outcome. Our results 
showed substantial differences between the 2 groups with re-
spect to the expression of ancillary biomarkers as well as in clin-
A B
C D
Fig. 3. In CXPA-NLD, focally positive staining for Bcl-2 (A) and p53 (B) was observed in the malignant components. Also, positive immunohistochemical staining for c-erbB-2 
(score 1+, [C]) and Glut-1 (high expression, [D]) was noted in some carcinoma cells.
%
72.7
63.6
90.9
72.7
27.3
9.1
18.2
*
*
16.7
0
50
83.3
16.7
CXPA-LD (n = 11)
CXPA-LD (n = 6)
50
33.3
  p53  c-erbB-2  VEGF  Glut-1  EGFR  Bcl-2  C-kit
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80
70
60
50
40
30
20
10
0
Fig. 4. Comparison of the expression rates of biomarkers between carcinoma ex pleo-
morphic adenomas with luminal and non-luminal differentiations in malignant com-
ponents. p53 and c-erbB-2 overexpression rates in CXPA-LD are significantly higher 
than those in CXPA-NLD. *Statistically significant (P ≤ 0.05)Kim JW, et al.  •  Immunoprofiles of Carcinoma ex Pleomorphic Adenoma
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ical features such as patient survival, tumor size, and gender. 
  With regard to the clinical outcome of CXPAs, many studies 
have demonstrated that the degree of tumor invasion is corre-
lated with the prognosis of CXPA, and only a few studies have 
characterized CXPA according to histological subtype. Recent-
ly, Katabi et al. (10) published a study with 43 CXPAs showing 
that the MC subtype tends to increase the risk of recurrence and 
that a higher frequency of MC was identified in frankly invasive 
tumors. In our study, frankly invasive tumors were more fre-
quent in CXPAs-NLD (100%) than in CXPS-LD (45.5%) like the 
previous study. However, the disease mortality rate was higher 
in CXPA-LD (27.3%) than in CXPA-NLD. And 66.7% of the dead 
had histologically high grade tumors. Therefore, we propose that 
not only invasiveness but also the histological features, such as 
subtype and grade, may be important prognostic factors. Katabi 
et al. did not describe the prognostic value of the histological 
grade in each carcinoma subtype but showed that histological 
parameters such as frequent mitoses (> 5 per 10 high-power 
fields), atypical mitosis, and necrosis correlated with disease-free 
survival. Also with regard to the evaluation of disease prognosis, 
consideration of the follow-up period is necessary. As a rule, low-
grade carcinomas of the salivary gland have a tendency to prog-
ress slowly and require a long-term follow-up of more than 5 yr 
(21). And there was a report indicating that longer follow-up led 
to greater mortality in CXPAs-NLD than in CXPAs-LD (10). We 
therefore, consider that more long-term follow-up is mandato-
ry for the exact evaluation of CXPA prognosis. 
  In previous reports, the positive rates for the p53 protein were 
0%-41% for PA and 45.2%-75% for CXPA, and some authors pos-
tulated that the p53 mutation was an early event in the malig-
nant transformation of PA (5, 7, 22, 23). The expression of the 2 
members of the epidermal growth factor receptor family, i.e., 
EGFR and c-erbB-2, has also been investigated in several stud-
ies as prognostic factors, and it was found that the amplification 
of the c-erbB-2 gene or overexpression of the c-erbB-2 protein 
was associated with poor prognosis in salivary gland malignan-
cies, including CXPA (24-26). Recently, DeRoche et al. suggest-
ed that markers such as c-erbB-2 and p53 may also be expressed 
in benign PA, and that these markers are not reliable for predict-
ing early carcinomatous transformation in PA (14). However, in 
our study, p53 was expressed in only 1 PA (score 4) among the 
17 tumor samples. Also, c-erbB-2 overexpression (score 3+) was 
significantly frequent in the carcinoma of the CXPA-LD group 
but was not present in the benign component of the CXPA-LD 
group or any component of CXPA-NLD. Therefore, we reason-
ably conclude that p53 and c-erB-B-2 biomarkers are associated 
with the carcinogenesis of CXPA-LD. In the absence of a che-
motherapeutic standard, we propose that c-erbB-2 expression 
should be assessed in CXPA, and that c-erbB-2-targeted thera-
py may provide significant clinical benefit in an appropriately 
selected patient group. Thus far, only a few patients who showed 
strong c-erbB-2 immunoreactivity and were treated with trastu-
zumab have been reported to show a sustained response (27). 
  VEGF induces endothelial differentiation, which is regulated 
by the hypoxia-responsive elements of the promoter region of 
the VEGF gene. Swelam et al. (28) proposed that tumor cells of 
PA produce VEGF in several functional forms, and that VEGF 
expression is controlled by the hypoxic condition of poorly vas-
cularized PA. Because stroma with scarring, hyalinization, and 
poor vascularization were observed in many CXPAs, we exam-
ined VEGF expression. Unexpectedly, the carcinoma cells were 
strongly stained in the LD group, whereas the VEGF expression 
pattern was nonspecific in the NLD group. There was no asso-
ciation between VEGF expression and stromal hyalinization.
  The interaction of c-kit transmembrane tyrosine kinase recep-
tor with its ligand, stem cell factor promotes phosphorylation 
and the activation of intracytoplasmic signal cascades, which 
are essential in embryogenesis, hematopoiesis, development, 
proliferation, and migration of germ cells. In salivary gland tu-
mors, there is only limited information on the immunoreaction 
of c-kit in a PA, and a study on c-kit expression in benign and 
malignant components of CXPA has not been reported (16, 29). 
We observed the loss of c-kit expression in the invasive and non-
invasive carcinoma components but not in the benign compo-
nent of CXPA-LD; this suggests that the loss of c-kit is associated 
with the malignant transformation of CXPA-LD and c-kit may 
serve as a useful ancillary diagnostic marker for CXPA-LD in 
combination with p53, c-erbB2, and VEGF. We think that further 
study with larger cohorts is needed to demonstrate the diagnos-
tic utility of c-kit for the differential diagnosis between early stage 
CXPA-LD and atypical PA, which it is sometimes challenging to 
distinguish them based on the morphologic features alone. In 
CXPA-NLD cases, c-kit was expressed in the most residual PAs 
(83.3%) and only in the inner luminal cells of an EMC; this re-
sult was similar to that observed in previous reports (29). These 
expression patterns also suggest that c-kit may play a role in the 
differentiation of common precursor cells of myoepithelial and 
ductal cells.
  In the evaluation of salivary gland tumors, the use of 18-fluo-
ro-2-deoxy-D-glucose positron emission tomography (
18F-FDG 
PET) remains a matter of debate, and there are only few reports 
describing the clinical significance of Glut-1 expression (18, 30). 
In this study, 
18F-FDG PET was used for the detection of prima-
ry tumor or metastasis in 6 tumor samples, the results of which 
showed an increase in the maximum standardized uptake val-
ue (SUV), with a mean value of 4.3 (range, 2.3-5.8). Four high-
grade CXPAs-LD (1 adenocarcinoma, NOS, 2 MEC, and 1 SDC) 
and 1 low-grade CXPA-NLD (EMC) had a maximum SUV of at 
least 3.7 and showed high Glut-1 expression. In 1 case of low-
grade CXPA-LD (adenocarcinoma, NOS subtype), the maximum 
SUV was 2.3, and it showed low expression of Glut-1. The results 
illustrate an association between high FDG uptake and Glut-1 Kim JW, et al.  •  Immunoprofiles of Carcinoma ex Pleomorphic Adenoma
1284   http://jkms.org http://dx.doi.org/10.3346/jkms.2011.26.10.1277
overexpression, and offer a basis for the clinical application of 
18F-FDG PET and Glut-1 for differential diagnosis between CXPA 
and PA.
  In order to investigate the possible relation between apopto-
sis and malignant transformation, we examined the frequency 
of Bcl-2 expression in CXPA (25). We observed a higher rate of 
positive staining for Bcl-2 in the malignant component of CXPA-
NLD, but the difference was not statistically significant.
  Although the number of cases analyzed in this study is limited, 
we show that the immunoprofiles and clinical course of CXPA 
differed according to its cellular differentiation. The distinct ex-
pression of biomarkers in CXPA-LD and CXPA-NLD indicates 
different mechanisms underlying carcinogenesis for the 2 CXPA 
subtypes. In CXPA-LD, the p53 mutation and growth factors/
receptors such as VEGF and c-erbB-2 are suggested to partici-
pate in malignant transformation. Our results also suggest that 
c-kit may play a role in progression from PA to CXPA-LD. These 
biomarkers may be useful for detecting a carcinomatous change 
in the PA, and some can be utilized for therapeutic purposes in 
the appropriately selected cases. Hence, we believe that it is im-
portant to report the histological subtype of CXPA and to assess 
potential biomarkers such as p53, VEGF, c-erbB-2, c-kit, and glut-
1 in diagnostic and therapeutic trials. 
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Clinicopathologic Features and Immunoprofiles Between Subgroups According to 
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Pathogenesis of carcinoma ex pleomorphic adenoma (CXPA) is unclear. To elucidate the clinicopathological implications of cellular 
differentiation in CXPA and the potential role of biomarkers in carcinogenesis, we analyzed 11 cases of CXPA with luminal 
differentiation (CXPA-LD) and 6 cases of CXPA with non-luminal differentiation (CXPA-NLD). The 5-yr survival rate of patients with 
CXPA- LD was 72.7%. p53, c-erbB-2, VEGF, and Glut-1 were more immunoreactive in carcinoma components than PAs. Also, 
carcinoma components frequently lacked c-kit expression. CXPAs-NLD with a larger mean tumor size (5.2 cm) than CXPAs-LD (3.3 cm, 
P = 0.040) remained disease-free without significant immunohistochemical expression. The immunoprofiles and clinical course of 
CXPA differed according to cellular differentiation. Therefore, it is important to report the histological subtype and to assess 
potential biomarkers.